Ambrisentan sodium NEW
| Price | $1520 | $1980 | $2500 |
| Package | 25mg | 50mg | 100mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: Ambrisentan sodium | CAS No.: 1386915-48-5 |
| Supply Ability: 10g | Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | Ambrisentan sodium |
| Description | Ambrosentan (BSF 208075) sodium is a selective and oral effective antagonist of ET type A receptor ( ETAR ). |
| In vitro | Ambrisentan sodium, an endothelin type A receptor antagonist [1], promotes Nrf2 activation. It mitigates the increase in endothelial permeability observed in BMEC monolayers after 24 hours of hypoxia, compared to a vehicle control. However, this protective effect of Ambrisentan is negated when BMEC are pre-treated with siRNA targeting Nrf2 [2]. |
| In vivo | In the study, Ambrisentan treatment resulted in a notably lower hepatic hydroxyproline content compared to the control (18.0 μg/g±6.1 μg/g vs 33.9 μg/g±13.5 μg/g liver, P=0.014). Furthermore, assessments of hepatic fibrosis using Sirius red staining and the evaluation of areas positive for α-smooth muscle actin—a marker of hepatic stellate cell activation—revealed significant reductions in the Ambrisentan group (0.46%±0.18% vs 1.11%±0.28%, P=0.0003; and 0.12%±0.08% vs 0.25%±0.11%, P=0.047, respectively). Additionally, hepatic RNA expression levels of procollagen-1 and tissue inhibitor of metalloproteinase-1 (TIMP-1) were reduced by 60% and 45%, respectively, in the Ambrisentan-treated group. It's important to note that Ambrisentan sodium's effect on inflammation, steatosis, and endothelin-related mRNA expression in the liver was not significant between groups. The findings suggest that Ambrisentan sodium mitigates hepatic fibrosis progression through the inhibition of hepatic stellate cell activation and a decrease in procollagen-1 and TIMP-1 gene expression, without influencing inflammation or steatosis. |
| Storage | Shipping with blue ice. |
Company Profile Introduction
TargetMol Chemicals Inc. is headquartered in Boston, MA, and specializes in products and services that serve the research needs of chemical and biological scientists worldwide. With a client base in 40+ countries, TargetMol has evolved into one of the biggest global research suppliers for compound libraries and small molecule compounds.
170+ Compound Libraries， 10000+ Noval Small Molecucles，16000+ Nature Compounds
TargetMol diligently updates and offers over 170 types of compound libraries and a wide range of high-quality research chemicals, including inhibitors, activators, natural products, peptides, antibodies , and novel life-science kits for laboratory and scientific use. In addition, our lab allows us to conduct CADD (computer-aided drug design) and chemical synthesis to meet the customization needs of our clients.
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $30.00/5mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
| $0.00/1g |
VIP1Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2024-10-11 | |
| $254.00/10g/Bag |
VIP4Y
|
Baoji Guokang Bio-Technology Co., Ltd.
|
2021-06-22 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY